Ocugen, Inc. (OCGN) SEC filings

OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30

$0.83−0.05 (-5.24%)

Close on Nov 13, 2026Market cap $280.72MP/E –Yield –

SEC filings

40 of Ocugen's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 15, 2026	SEC EDGAR
Current report	8-K	Oct 5, 2026	Oct 6, 2026	SEC EDGAR
Current report	8-K	Sep 21, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Sep 1, 2026	Sep 8, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Sep 21, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	8-K	Jun 11, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 20, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 4, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 4, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 4, 2026	SEC EDGAR
Current report	8-K	Feb 9, 2026	Feb 9, 2026	SEC EDGAR
Current report	8-K	Jan 22, 2026	Jan 23, 2026	SEC EDGAR
Current report	8-K	Jan 20, 2026	Jan 21, 2026	SEC EDGAR
Current report	8-K	Jan 15, 2026	Jan 15, 2026	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 18, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Sep 16, 2025	Sep 18, 2025	SEC EDGAR
Current report	8-K	Sep 11, 2025	Sep 16, 2025	SEC EDGAR
Current report	8-K	Aug 29, 2025	Sep 5, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 4, 2025	SEC EDGAR
Current report	8-K	Aug 1, 2025	Aug 1, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Ocugen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Nov 12, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OCGN.

Compare: OCGN vs PRME · OCGN vs FATE · OCGN vs LCTX · OCGN vs TSHA · OCGN vs CRIS

Revenue growth8.8% · median -13.1%

Operating margin-1564.3% · median -2760.0%

Net margin-1481.0% · median -2619.6%

Company	Revenue	Growth
LCTX	$10.84M	+0.2%
TSHA	$5.49M	-13.1%
FATE	$4.75M	-33.4%
OCGN	$4.41M	+8.8%
PRME	–	–
CRIS	–	–

Company

Next earnings (est.): Mar 3, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 116
Held by institutions: 42.8%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1372299

Advertisement
300 × 250

See a number that looks wrong?